Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). On August 22, BIIB and Eisai Co.

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The ...

Dr. Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in ...

Tony Downs was a powerhouse lawyer with an uncanny memory before the memory-robbing disease took hold. Now, he and his wife are hoping Leqembi, a newly approved drug, will help slow his decline.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company ...

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

France-based clinical research company Aixial Group is consolidating clinical data from one of its business units into ...

This stance contrasts with the Medicines and Healthcare products Regulatory Agency (MHRA), which has endorsed the drug, developed by Eisai and marketed as Leqembi, as safe and effective.

Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. The Medicines and Healthcare products ...